PIPR is currently showing a neutral headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently no clear earnings read.
HEADLINE TAKE: The current headline mix looks balanced, so the overall news tone reads neutral right now.
Change stock
Search another ticker to view its latest news page.
Full chart, indicators and drawing tools on TradingView. Move to Platforms when you are ready to act.
MyStockHarbor
NEWS SCORE
50/100
Neutral
Bearish
Neutral
Bullish
Earnings Tone
78
Good based on actual EPS/revenue
Confidence
Low
Headline depth
Last Price
$77.75
Trend Context
Mixed / range
Latest briefing
What's happening with PIPR
businesswire.com29 Jun 2026
Piper Sandler Expands Restructuring Group With the Addition of John D'Amico
NEW YORK--(BUSINESS WIRE)--Piper Sandler Companies (NYSE: PIPR), a leading investment bank, is pleased to announce the addition of John D'Amico as a managing director in the Piper Sandler restructuring group. D'Amico will be focused on advising a broad range of clients in complex restructurings and special situation transactions.With approximately 25 years of investment banking and corporate advisory experience, D'Amico has advised companies, boards of directors, official and ad hoc creditor com.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
gurufocus.com10 Jun 2026
Is Piper Sandler Cos (PIPR) a Bargain After 3.3% Drop? GF Value Says Undervalued
On June 10, 2026, Piper Sandler Cos (PIPR) shares fell 3.3% today, closing at $76.53. The stock has fluctuated within a 52-week range of $62.49 to $95.07, showc
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
prnewswire.com4 Jun 2026
CereVasc, Inc. Announces Over-Subscribed $85 Million Series C Financing to Advance its Novel eShunt® System for the Treatment of Normal Pressure Hydrocephalus
Financing led by Piper Sandler Merchant Banking, with participation from new investors Johnson & Johnson Innovation – JJDC, Inc., Johnson & Johnson's corporate venture capital arm, and Medtronic Participation by existing investors, including Bain Capital Life Sciences and Perceptive Xontogeny Venture Funds Proceeds will support the conclusion of the STRIDE pivotal trial, continued operational scale-up, advancement of regulatory work toward a future Premarket Approval (PMA) submission to the FDA, and preparations fo…
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
Older updates drop into a lighter feed
businesswire.com
2 Jun 2026
Piper Sandler Appoints New Co-Heads of Services and Industrials Investment Banking and Enhances Focus on Private Equity Advisory Business
